Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AbbVie to Begin Clinical Development of Schizophrenia Drug in Japan
August 18, 2021
- Japan Pharma Market Delivers 1st Growth in 5 Qtrs in April-June: IQVIA
August 18, 2021
- Teva Takeda Set to Roll Out 2nd Blopress AG but Denies Competition with ASKA
August 17, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- OBP-601 to Enter US PII for Neurodegenerative Diseases: Oncolys
August 17, 2021
- Boehringer Joins NCC’s Rare Cancer Project
August 16, 2021
- Sandoz Curbs Shipments of Leprosy Drug, Hints at Supply Halt
August 16, 2021
- Probe Panel Urges Ono to Establish Foundation to Handle Scholarship Donations after Bribery Case
August 16, 2021
- Ono, MiraBiologics Ink Biologics Discovery Deal
August 16, 2021
- Towa’s Shipment Restriction List Now Expands to 352 Products
August 16, 2021
- Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
- Hisamitsu Ordered to Suspend Biz over Salonpas OTC Data Tampering
August 13, 2021
- Lenvima Plus Keytruda Approved for RCC in US
August 13, 2021
- Reps’ Face-to-Face Meetings Remain Flat YOY in June; Growth Seen across All Channels from May: Intage
August 13, 2021
- Morimoto Pharma Aims at Commercial Production of Freeze-Dried Vaccine in FY2022
August 12, 2021
- Japan Ethical Drug Sales Rise 2.1% in June: Crecon
August 12, 2021
- Ex-HBS Dean Nitin Nohria Tapped as Board Chair at Rakuten Medical
August 12, 2021
- Cost-Effectiveness Simulation Model Developed for Type 2 Diabetes: Novo
August 12, 2021
- Orizuru Therapeutics Boots Up to Take Over iPSC Assets from T-CiRA, Eyes IPO in 2026
August 11, 2021
- Santen Snags EMEA Rights to Sydnexis’ Myopia Drug
August 11, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…